Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Avalyn Pharma (Nasdaq: AVLN) announced two poster presentations at the European Respiratory Society International Congress 2026, held September 5–9, 2026, in Barcelona.

Rhea-AI Summary

Avalyn Pharma (Nasdaq: AVLN) announced two poster presentations at the European Respiratory Society International Congress 2026, held September 5–9, 2026, in Barcelona. On September 7, 2026, posters will cover IPF patient perspectives on clinical trial participation and in silico modeling of AP01 lung aerosol distribution. Presentations will also be accessible on the company’s website.

Argus Aug 25 session 4 alerts

+1.35% close to close 2.6x rel. volume Open Argus

Details

News Market Reaction – AVLN

$1.63B Market Cap

On Aug 25, the first trading day after this news, AVLN closed 1.35% above the previous close. Our momentum scanner recorded 4 alerts in the available session data. Relative volume reached 2.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 25 session.

Key Figures

Upcoming poster presentations: 2 presentations Congress dates: September 5-9, 2026 First presentation date: September 7, 2026 +3 more

Upcoming poster presentations

2 presentations

ERS International Congress 2026

Congress dates

September 5-9, 2026

Barcelona, Spain

First presentation date

September 7, 2026

Poster PA3014

First presentation time

8:00-9:30 a.m. GMT

Poster PA3014

Second presentation date

September 7, 2026

Poster PA4377

Second presentation time

12:30-2:00 p.m. GMT

Poster PA4377

Historical Context

5 past events · Latest: Aug 12

5 events

1. Aug 12

   2Q26 earnings report

   24h Move

   +5.4%

   MIST enrollment completed above target and cash runway extended into 2029

2. Jun 17

   MIST enrollment completion

   24h Move

   +4.4%

   Phase 2b MIST trial reached target enrollment of 375 patients

3. Jun 03

   1Q26 earnings report

   24h Move

   +2.6%

   IPO proceeds strengthened liquidity and supported projected funding into 2029

4. May 27

   Healthcare conference presentation

   24h Move

   +0.5%

   Company overview presentation scheduled for the Jefferies Global Healthcare Conference

5. May 21

   Long-term AP01 data

   24h Move

   +1.4%

   Updated AP01 tolerability data scheduled for EULAR poster presentation

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ipf, in silico modeling, nebulized, aerosol distribution

4 terms

ipf medical

"Understanding patient perspectives on IPF clinical trial participation"

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease where scar tissue builds up in the lungs for reasons doctors don't fully understand, making it harder to breathe over time. For investors, IPF matters because it represents a clear medical need and a regulated market for treatments, so progress in clinical trials, regulatory approvals, or new therapies can materially affect the value of companies working on drugs or devices for this condition—much like a new road that could open access to a previously hard-to-reach town.

in silico modeling technical

"In silico modeling of a novel nebulized pirfenidone formulation"

Computer-based simulations of biological, chemical, or medical processes used to predict how a drug, device, or treatment will behave without physical experiments. Like a flight simulator for medicine, these virtual models let researchers test scenarios, estimate safety or effectiveness, and explore dosing or trial designs; that matters to investors because results can affect development speed, cost, regulatory filings, and the perceived risk or value of a medical program.

nebulized medical

"a novel nebulized pirfenidone formulation (AP01)"

Nebulized means a liquid medicine has been turned into a fine mist so it can be breathed directly into the airways and lungs using a small device. For investors, nebulized delivery matters because it can change how well a treatment works, who can use it, the types of devices and manufacturing needed, and the regulatory steps required — think of it like delivering medicine with a spray instead of a pill.

aerosol distribution medical

"predicts aerosol distribution throughout the lung"

Aerosol distribution is how tiny liquid or solid particles suspended in air are spread and settle when emitted from a device or source — imagine how perfume fills and drifts across a room. Investors care because it affects product safety, effectiveness, regulatory approval, manufacturing controls, and liability: how particles travel determines whether a drug delivery method, industrial process, or consumer product meets health rules and market acceptance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced two upcoming poster presentations at the European Respiratory Society (ERS) International Congress 2026, being held September 5-9, 2026, in Barcelona, Spain.

ERS 2026 Poster Presentation Details:

Poster Title: Understanding patient perspectives on IPF clinical trial participation: Preferences, motivations, and comfort with study design
Poster Session: #246: Real-world studies: acute exacerbations and pulmonary fibrosis treatment
Presenting Author: Brittany Davis, Ph.D., Avalyn Pharma
Location: PS-34, Poster #: PA3014
Date and Time: September 7, 2026, between 8:00 a.m. – 9:30 a.m. GMT (4:00 a.m. – 5:30 a.m. EDT)

Poster Title: In silico modeling of a novel nebulized pirfenidone formulation (AP01) predicts aerosol distribution throughout the lung
Poster Session: #378: Molecular mechanisms and clinical strategies in interstitial lung diseases
Author: Michelle Palacios, Ph.D., DABT, Avalyn Pharma
Session: PS-9, Poster #: PA4377
Date and Time: September 7, 2026, between 12:30 p.m. – 2:00 p.m. GMT (8:30 a.m. – 10:00 a.m. EDT)

See the ERS online program for more details. The presentations will also be accessible on the company’s website.

About Avalyn Pharma
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.

Investor Contact:
Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
ir@avalynpharma.com

Media Contact:
Precision AQ
avalyn@precisionaq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avalyn Pharma (NASDAQ: AVLN) announce for the ERS International Congress 2026?

Avalyn Pharma announced two poster presentations at the European Respiratory Society International Congress 2026. According to Avalyn Pharma, these will highlight patient perspectives in idiopathic pulmonary fibrosis (IPF) clinical trials and in silico modeling of aerosol distribution for its nebulized pirfenidone formulation AP01.

When and where will Avalyn Pharma present at ERS International Congress 2026?

Avalyn Pharma will present two posters on September 7, 2026, at ERS 2026 in Barcelona, Spain. According to Avalyn Pharma, sessions run between 8:00–9:30 a.m. GMT and 12:30–2:00 p.m. GMT, covering IPF trial perspectives and AP01 aerosol modeling.

What is the focus of Avalyn Pharma’s IPF clinical trial design poster at ERS 2026?

The IPF poster focuses on understanding patient perspectives on clinical trial participation, including preferences, motivations, and comfort with study design. According to Avalyn Pharma, it is part of Poster Session #246 on real-world studies for acute exacerbations and pulmonary fibrosis treatment.

What will Avalyn Pharma present about AP01 at ERS International Congress 2026?

Avalyn Pharma will present a poster on in silico modeling of its novel nebulized pirfenidone formulation, AP01, predicting aerosol distribution throughout the lung. According to Avalyn Pharma, this work appears in Poster Session #378 on molecular mechanisms and clinical strategies in interstitial lung diseases.

How can investors access Avalyn Pharma’s ERS 2026 poster presentations after the congress?

The poster presentations will be accessible on Avalyn Pharma’s website. According to Avalyn Pharma, details are also available through the ERS online program, allowing investors and clinicians to review information on IPF patient perspectives and AP01 aerosol distribution modeling after the event.

Who are the presenting authors for Avalyn Pharma’s ERS 2026 posters?

Brittany Davis, Ph.D., will present the IPF patient perspectives poster, and Michelle Palacios, Ph.D., DABT, will present the AP01 modeling poster. According to Avalyn Pharma, their work will be shown in sessions PS-34 (PA3014) and PS-9 (PA4377) on September 7, 2026.